Clinical trial · Observational
REal World MAIA UK OutcomEs
A Retrospective Study of Clinical Outcomes in Newly Diagnosed, Transplant Ineligible Multiple Myeloma Patients Treated With Daratumumab, Lenalidomide and Dexamethasone (DRd) Outside of Clinical Trials in the UK
NCT07532473CI-TRIAL-00108843REMAKEnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloma | Multiple Myeloma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall response rate (OOR) at 12 months
- timeFrame
- 12 months
- description
- Proportion with partial response (PR) or better (per IMWG criteria).
- measure
- Real-world dosing strategy for DRd - starting doses of Daratumumab, Lenalidomide and dexamethasone in cycle 1 and relative dose intensity at 12 months
- timeFrame
- 12 months
- description
- % of patients who have had a dose adjustment in any of the DRD treatment components within the first 12 months of treatment
Secondary outcomes (7)
- measure
- Progression -Free Survival (PFS) at 12 and 24 months
- timeFrame
- 12 months and 24 months
- description
- Time from first dose to documented disease progression or death (whichever first) Median time to disease progression or death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Diagnosis of NDMM * Not eligible for autologous stem cell transplant at diagnosis * Received frontline DRd treatment following NICE approval (post-September 2023) * Minimum 3 months of follow-up data available Exclusion Criteria: * Participation in an interventional clinical trial for first-line therapy * Insufficient treatment or follow-up data for analysis * DRd used in relapsed/refractory setting rather than newly diagnosed disease
References
Publications (0)
Data not yet available
No reference posted for this study.